AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO) from its SEC filings: 2025 revenue $54.0 million (+48% vs the year before), net margin -764%, free cash flow -$377.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $54.0 million |
| Revenue growth | +48% |
| Net income | -$413.0 million |
| Net margin | -764.4% |
| Free cash flow | -$377.3 million |
| Diluted EPS | $-7.12 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +259% |
| Cash | $99.6 million |
| Share count, 1 year | +3% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.